CTOs on the Move

Adaptive Biotechnologies

www.adaptivebiotech.com

 
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
David Arbo
 Sr Director of Information Technology Profile
Josh Schmidt
 Senior Director, Information Security Profile
Mark Adams
 Chief Technical Officer Profile
Mark Adams
 Chief Operating Officer Profile

Funding

Adaptive Biotechnologies raised $195M on 05/07/2015

Similar Companies

Genetics Center

Genetics Center is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurogene

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.

BIOCiS

BIOCiS is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.

Reverie Labs

Engineering next‑generation, brain‑penetrant cancer therapies.